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Hematopoietic cell transplantation (HCT) remains the sole available curative option for patients with
b-thalassemia major. Expanded and improved supportive therapies for thalassemia now routinely extend the
life span of affected individuals well into adulthood. Consequently, in regions of the world where this care is
readily available, HCT has been pursued infrequently, in part owing to concerns about an expected lack of
balance between risks and beneﬁts. More recently, however, recognition of signiﬁcant health problems in
older patients with thalassemia, along with recognition of increased risks of graft-versus-host disease
(GVHD), graft rejection, and impaired organ function leading to inferior HCT outcomes in this particular
group, seem to be turning the wheels and tipping the balance again in the direction of consideration for
earlier HCTs. In contrast, in countries where thalassemia is most prevalent (>100,000 new children born each
year in Middle East and southeast Asia), lack of supportive care standards together with often insufﬁcient
access to dedicated health care facilities, results in the majority of these children not reaching adulthood,
further supporting the need for expanded access to HCT for these patients. The cost of HCT is equivalent to
that of a few years of noncurative supportive care, such that HCT in low-risk young children with
a compatible sibling is justiﬁed not only medically and ethically but also ﬁnancially. International cooperation
can play a major role in increasing access to safe and affordable HCT in countries where there is a considerable
shortage of transplantation centers. In this article, we review the current status of bone marrow trans-
plantation for thalassemia major, with particular emphasis on a global prospective.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
b-thalassemia is the most common genetic disease
worldwide. Although improvements in conservative treat-
ment have improved the prognosis of thalassemia consid-
erably, disease- and treatment-related complications in
affected patients progress over time, causing severe
morbidity and shortened life expectancy, along with
substantial health care expenses in countries with high
carrier rates, ranging between 5% and 30% [1]. Signiﬁcant
progress in hematopoietic cell transplantation (HCT) for
thalassemia has been made over the last 3 decades [2], such
that disease-free survival (DFS) rates exceeding 80% have
been consistently reported in young, low-risk patients with
a histocompatible family donor [3]. In addition to improved
DFS, HCT is also associated with improved quality of life.TRANSPLANTATION RISK ASSESSMENT
The largest experience with HCT for thalassemia comes
from Pesaro, Italy, where a standard pretransplantation risk
assessment was developed. The standard “Pesaro” risk
stratiﬁcation scheme [4] based on liver size by physical
examination, ﬁbrosis detected on liver biopsy, and chelation
history has been used for years to risk stratify patients before
HCT and has been shown to correlate well withedgment on page S73.
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readily applicable in settings where liver biopsy analysis
might not be performed routinely. Moreover, this scheme
was developed largely in patients with regular access to RBC
transfusions and might not apply to chronically under-
transfused children in whom hepatomegaly may not neces-
sarily reﬂect severe iron overload and can potentially be
partially corrected with an appropriate pre-HCT transfusion
program. More recently, alternative-risk group assignments
independent of liver biopsy have been proposed. One such
risk stratiﬁcation scheme based primarily on age and liver
size reported cure rates exceeding 70% for MSD HCT in
children aged <7 years with liver palpated 5 cm below the
costal margin, regardless of chelation history or liver ﬁbrosis
[5]. A report from the Center for International Blood and
Marrow Transplant Research (CIBMTR) on results of HLA-
matched sibling HCT for thalassemia major performed in
locations other than Italy conﬁrmed that age at trans-
plantation and liver size are independent predictors of
mortality after transplantation. In patients aged<7 years and
without hepatomegaly (liver palpated <2 cm below the
costal margin), the 5-year probabilities of OS and DFS were
98% and 94%, respectively [6].SPLENECTOMY AND HCT
Many children with thalassemia who do not receive
optimal care and regular transfusions will have hep-
atosplenomegaly. Enlarged spleen per se is not associated
with higher rejection rates but may increase transfusion
requirements and delay engraftment [7]. Retrospective dataTransplantation.
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transplantation-related mortality [7], but whether this is an
independent risk factor is not clear [5]. At present, most
centers probably would not recommend routine splenec-
tomy before HCT for thalassemia.
HEPATITIS C
Hepatitis C virus (HCV) infection remains an additional
pretransplantation consideration in patients from many
developing countries with a history of multiple transfusions
[8] and is associated with progression to both liver ﬁbrosis
and hepatocellular carcinoma [9]. Reportedly, however, it can
clear spontaneously in approximately one-third of patients.
To date, there is no evidence that HCT has any inﬂuence on
the course of HCV infection or vice versa [10]. In fact, given
the synergism of HCV and iron overload in accelerating the
progression of liver ﬁbrosis [11], HCV positivity might lend
support to the decision tomove forwardwith HCT in selected
patients.
TRANSPLANTATION CONSIDERATIONS
Results of HCT for patients with thalassemia have
improved steadily over the last 3 decades owing to the
development of new preparative regimens and effective
control of transplantation-related complications. The earliest
studies used conditioning regimens with a myeloablative
backbone of busulfan and cyclophosphamide for matched
sibling donor (MSD) HCT and demonstrated successful
outcomes.
Results from the Italian group for MSD HCT for Pesaro
class I, II, and III recipients show thalassemia-free survival
probabilities of 87%, 85%, and 80%, respectively. Despite these
improvements, however, pretransplantation transfusion
exposures and organ damage from iron overload continue to
have a negative impact on transplantation outcomes. In
a recent update, transplantation-related mortality was 3%
in class I or II patients and 10% in class III patients, and 8% to
12% of pediatric recipients experienced graft rejection after
HCT [12].
The most recent MSD HCT experience from outside Italy
comes from the CIBMTR data, which conﬁrm that HLA-MSD
HCT for thalassemia major is a suitable therapeutic option to
consider, with DFS rates exceeding 90% in children with
good-risk features. However, as noted in the initial Pesaro
experience, children with high-risk features fared much
worse, with an event-free survival rate approaching 50% [6].
Modiﬁcations to the transplantation regimen that might
improve the safety of the procedure are important; for
example, investigators in Italy have reduced the cyclophos-
phamide dose in high-risk patients [13]. Alternatively,
replacing cyclophosphamide with ﬂudarabine might also
mitigate the risk of signiﬁcant transplantation-related
toxicity [14]. In contrast, the use of antithymocyte globulin
does not appear to reduce the risk of graft failure.
The major limitation of HCT for thalassemia is the lack of
an HLA-identical sibling donor for the majority of recipients.
Currently, with high-resolution HLA typing, it is possible to
perform HCT with unrelated donor grafts for thalassemia;
however, this is associated with signiﬁcant treatment-
related mortality, graft rejection, and chronic GVHD.
Patients who lack both an MRD and a suitable unrelated
donor could also beneﬁt fromhaploidentical mother-to-child
transplantation. Although the number of patients under-
going HCT using this strategy is small, the results of this
transplantation approach are encouraging.Our current understanding of stable mixed chimerism in
patients with hemoglobinopathies also provides a rationale
for the use of less-intensive conditioning regimens. In this
regard, several recent patient series have shown progress in
addressing the problems of graft rejection and regimen-
related toxicity, which in turn should help expand the use
of HCT even beyond the scope of MSD HCT. Examples include
extending the duration and intensity of pretransplantation
immunosuppression by administering azathioprine and
hydroxyurea 6 weeks before HCT and adding ﬂudarabine to
the conditioning regimen. The use of treosulfan in lieu of
busulfan also appeared to generate excellent results in the
unrelated donor setting [15].
POST-HCT COMPLICATIONS
Veno-Occlusive Disease of the Liver
VOD does not seem to be a major or frequent complica-
tion in the Italian experience of more than 1000 HCTs for
thalassemia (P. Sodani, personal communication). The inci-
dence of VOD is higher in Indian patients [16]. Potential
explanations for this discrepancy include differences in
busulfan dosing and/or sensitivity related to pharmaco-
genetic variables among populations. However, a low rate of
VOD, similar to the Italian experience has also been reported
in Pakistani children, who have a more similar genetic
background to Indians [17].
Late Affects
Data on long-term outcomes after HCT for thalassemia
remain limited. Second malignancies after HCT do not seem
to be a major issue, possibly because conditioning regimens
generally do not incorporate irradiation. In contrast, infer-
tility remains common, occurring in approximately 60% of
patients undergoing HCT for thalassemia regardless of sex. In
countries where thalassemia is most prevalent, this problem
might be particularly relevant, and fertility preservation
strategies like sperm banking and ovarian tissue cryopres-
ervation should be considered whenever feasible. In addi-
tion, fertility problems should be clearly addressed with
patients during pre-HCT counseling and consent procedures.
ALTERNATIVE DONOR HCT FOR THALASSEMIA IN
DEVELOPING COUNTRIES
Despite large average family sizes in many thalassemia-
prone areas, an MRD might not be available for the majority
of children with thalassemia. Having a thalassemic child is
a dramatic event per se that often dissuades parents from
taking the risk of havingother childrenwith thedisease, and it
can also drainmost of a family’s resources. It should be kept in
mind, however, that particularly in areas with high rates of
consanguineous marriages, MRDs may be found in the
extended family, and HLA typing of ﬁrst-degree relatives,
starting with grandparents, who are often healthy and young
enough to donate marrow, should be considered [18]. This
may be especially useful in families with 2 children with
thalassemia, which is not infrequent, where there is double
the chance that at least 1 of the 2 children will ﬁnd a match.
Unrelated donors (URDs) have been used successfully;
however, the need for extended histocompatibility matching
hinders identiﬁcation of suitable URDs, most of who belong
to ethnic groups underrepresented in donor registries [19].
The prohibitive cost of donor searches and unrelatedmarrow
procurement is another limiting factor.
In the European experience, unrelated cord blood trans-
plantation for thalassemia major has been associated with
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and mortality [20], making unrelated cord blood an unde-
sirable stem cell source. Moreover, cord blood is a very
expensive stem cell product subject to stringent quality
control and regulatory standards. The same technical and
cost-related issues apply to related cord blood trans-
plantation. In fact, cost is a major factor determinant of any
transplantation procedure for lower-income patients with
thalassemia. In addition, the elevated risk of extensive
chronic GVHD, which actually might worsen quality of life
compared with thalassemia itself, should be taken into
consideration.
Partially matched related donorsdtypically a parentdare
readily accessible. In the sole series published to date, in
which extensively T celledepleted maternal stem cells were
used for HCT, 14 of 22 patients with thalassemia (63%) ach-
ieved transfusion independence. Transplantation-related
mortality was 9%, the rejection rate was 28%, and no patient
developed acute or chronic GVHD [21]. The use of post-HCT
high-dose cyclophosphamide as a means of bidirectional
in vivo allodepletion with its associated faster immunologic
recovery, tolerable delays in hematologic engraftment [22],
along with decreased costs, could potentially be an attractive
and realistic alternative in lower-resource settings.
INTERNATIONAL COOPERATION PROJECTS: THE
CURE2CHILDREN FOUNDATION EXPERIENCE
A nonproﬁt project supporting HCT for thalassemia in
emerging countries, the Cure2Children Foundation (C2C)
was developed by a group of Italian parents who lost their
children to cancer. C2C’s primary mission is to increase
sustainable access to care for all children with cancer and
severe blood disorders.
This initiative aimed at offering HCT to low-risk children
with a compatible donor on a nonproﬁt basis directly in
Pakistan. The primary objective was to obtain cure rates
comparable to international standards in young low-risk
children with thalassemia with an available compatible
sibling donor, while minimizing expenses by implementing
primarily evidence-based recommendations. Although the
children were admitted to single rooms with private bath-
rooms but stringent air-control systems, masks and gowns
were not required. Nursing personnel were speciﬁcally
trained on strict handwashing and central line management
and were exclusively dedicated to the transplantation unit.
The nurse:patient ratio was limited to 1:3. Onsite training
was performed by a team of experienced C2C professionals.
This included 3 weeks of focused hands-on training for the
initial 2 transplantation procedures, followed by ongoing 24/
7 online intensive assistance and tutoring via established
management/conferencing tools. Patient-speciﬁc treatment
plans designed according to good clinical practice, with the
goal of minimizing prescription errors, were also used and
provided clear and simple operating instructions to point-of-
care professionals. This model was implemented in 2 newly
established transplantation units, one in Islamabad, Pakistan,
and the other in Jaipur, India.
The predetermined HCT strategy included a preparative
regimen containing thiotepa, busulfan (oral), and cyclo-
phosphamide. The stem cell source was unmodiﬁed bone
marrow, and GVHD prophylaxis consisted of cyclosporine,
methotrexate, and prednisone. This regimen was based on
the protocol used by Lucarelli’s group in younger children
with thalassemia, in which thiotepa was introduced to
reduce the rejection rate observed with a standard busulfan/cyclophosphamide regimen [23]. All patients received irra-
diated blood products, and cytomegalovirus DNA copies
were monitored by real-time PCR.
For the ﬁrst 12 children, aged <6 years with liver
size 2 cm, thalassemia-free survival was 91% at a median
follow-up of 24 months. One child died from sepsis/menin-
gitis, possibly tuberculosis. None developed severe acute or
extensive GVHD, overt cytomegalovirus disease, or invasive
aspergillosis.
In both Islamabad and Jaipur, the cost of setting up
a 3-bed transplantation unit was less than $100,000 USD,
and the cost of HCT for each patient was in the $10,000 USD
range. A patient coordinator, as well as housing and
a monthly allowance, were provided as needed throughout
the ﬁrst 8 months post-HCT.
POTENTIAL INDIRECT POSITIVE EFFECTS OF HCT
Involvement of Extended Family in Prevention Programs
Screening and prevention remains the only realistic way
to effectively control thalassemia. In countries where this
disease is most prevalent, there is a general lack of preven-
tive programs. Previous studies have shown that cascade
screening, stemming from an affected case or a carrier, may
identify a substantial proportion, if not the majority, of cases.
This is particularly true in cultures with high rates consan-
guinity, where the thalassemia gene tends to remain “trap-
ped” within extended families [24]. These families might be
engaged in screening, counseling, and prevention programs
through the offer of cure for their affected children, although,
unfortunately, there is often resistance to performing a test
that might stigmatize a thalassemia carrier as “less ﬁt.”
Promotion of Compliance with Supportive Care
Offering a realistic prospect of a deﬁnitive cure is a strong
incentive for many families to better comply with supportive
care for their affected children.
Health Care Empowerment and Higher Medical
Education
Many factors contribute to HCT for thalassemia providing
a unique opportunity for capacity building, including the
following: (1) Thalassemia represents the major indication
for HCT in many developing areas; (2) young low-risk chil-
dren may enjoy very high success rates after HCT with good
quality of life; (3) HCT for thalassemia is ﬁnancially justiﬁed;
(4) in the wide spectrum of HCT procedures, the procedure
for low-risk thalassemia is relatively simple, safe, and
amenable to focused training and task-shift strategies; and
(5) increasing evidence suggests that complex infection
control environments with HEPA ﬁltration and positive
pressure gradients might not be required.
In the Cure2Children-supported thalassemia HCT project
in developing countries, results in low-risk patients have
been comparable to those obtained in Italy with a fraction of
the cost (ie, approximately $10,000 USD per transplantation).
Moreover, HCT for thalassemia was performed by personnel
with limited experience within a structured training and
collaboration program.
CONCLUSION
Thalassemia is one of the most prevalent chronic life-
threatening noncommunicable diseases affecting children
in lower-income regions worldwide. There is a growing
demand for HCT for thalassemia, which provides the only
curative treatment for these children. In low-risk young
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obtained with good quality of life and a fraction of the costs
compared with afﬂuent countries. HCT also reduces the
ﬁnancial burden of thalassemia on affected families and
health care systems and may help increase compliance with
supportive care, as well as awareness of prevention.
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